Stemness and chemotherapeutic drug resistance induced by EIF5A2 overexpression in esophageal squamous cell carcinoma

Autor: Dan Xie, Bao Zhu Zhang, Jing-Ping Yun, Yan Li, Xiao dong Li, Hong Yang, Xin Yuan Guan, Xiaojiao Ban, Ying Zhou, Ting Ting Zeng, Lei Li
Jazyk: angličtina
Rok vydání: 2015
Předmět:
Oncology
Male
Pathology
Esophageal Neoplasms
medicine.medical_treatment
Apoptosis
Drug resistance
Docetaxel
Kaplan-Meier Estimate
chemistry.chemical_compound
Peptide Initiation Factors
EIF5A2
Medicine
Reverse Transcriptase Polymerase Chain Reaction
chemoresistance
RNA-Binding Proteins
Esophageal cancer
Middle Aged
Immunohistochemistry
Gene Expression Regulation
Neoplastic
Paclitaxel
Carcinoma
Squamous Cell
Neoplastic Stem Cells
Female
Taxoids
Fluorouracil
medicine.drug
Research Paper
Adult
medicine.medical_specialty
Combination therapy
Blotting
Western
Antineoplastic Agents
stemness
Internal medicine
Cell Line
Tumor
Humans
neoplasms
Aged
Retrospective Studies
Chemotherapy
Taxane
business.industry
Cancer
medicine.disease
digestive system diseases
chemistry
esophageal squamous cell carcinoma (ESCC)
Drug Resistance
Neoplasm
business
Zdroj: Oncotarget
ISSN: 1949-2553
Popis: // Hong Yang 1, 2 , Xiao-dong Li 1, 2 , Ying Zhou 1 , Xiaojiao Ban 1 , Ting-ting Zeng 1 , Lei Li 1 , Bao-zhu Zhang 1 , Jingping Yun 1 , Dan Xie 1 , Xin-Yuan Guan 1, 3 , Yan Li 1 1 Sun Yat-sen University Cancer Center, State key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China 2 Guangdong Esophageal Cancer Institute, Guangzhou, China 3 Department of Clinical Oncology, The University of Hong Kong, Hong Kong, China Correspondence to: Yan Li, e-mail: liy6@mail.sysu.edu.cn Keywords: esophageal squamous cell carcinoma (ESCC), EIF5A2, stemness, chemoresistance Received: June 19, 2015 Accepted: July 08, 2015 Published: July 20, 2015 ABSTRACT Esophageal squamous cell carcinoma (ESCC) is one of the most lethal malignancies of the digestive tract in East Asian countries. Multimodal therapies, including adjuvant chemotherapy and neo-adjuvant chemotherapy, have become more often used for patients with advanced ESCC. However, the chemotherapy effect is often limited by patients’ drug resistance. This study demonstrated that EIF5A2 (eukaryotic translation initiation factor 5A2) overexpression induced stemness and chemoresistance in ESCC cells. We showed that EIF5A2 overexpression in ESCC cells resulted in increased chemoresistance to 5-fluorouracil (5-FU), docetaxel and taxol. In contrast, shRNAs suppressing eIF5A2 increased tumor sensitivity to these chemotherapeutic drugs. In addition, EIF5A2 overexpression was correlated with a poorer overall survival in patients with ESCC who underwent taxane-based chemotherapy after esophagectomy ( P < 0.05). Based on these results, we suggest that EIF5A2 could be a predictive biomarker for selecting appropriate chemo-treatment for ESCC patients and EIF5A2 inhibitors might be considered as combination therapy to enhance chemosensitivity in patients with ESCC.
Databáze: OpenAIRE
Externí odkaz: